Kopran Limited · NSE:KOPRAN
Kopran — Q3 FY2023-24 Earnings Presentation
19 slides from Kopran's earnings presentation, 2024
Slide 1: One Direction, Endless Opportunities. Corporate Presentation Q3 FY 2023-24
ONE DIRECTION, ENDLESS OPPORTUNITIES. CORPORATE PRESENTATION Q3 FY 2023-24 KOPRAN LIMITED 1
Slide 2: Safe Harbour Statement
SAFE HARBOUR STATEMENT This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered o
Slide 3: Kopran Limited: A Global Pharmaceutical Company
KOPRAN LIMITED A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International Quality 50+ Formulations and Active Pharmaceutical Ingredients (APIs) globally Nations - Export Reach State-of-the-art manufacturing facilities and products with various accredit
Slide 4: Business Overview API
BUSINESS OVERVIEW API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENTS Development, manufacturing and Anti-hypertensive sale of diverse APIs and Advanced Atenolol Macrolide Intermediates Cephalosporins - Non-Sterile Neuromodulator & Sterile One of the leaders in Atenolol Urologic
Slide 5: Business Overview Formulations
BUSINESS OVERVIEW FORMULATIONS FORMULATIONS VERTICAL PRODUCT SEGMENTS Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs Catering 100% export markets of both Regulated and Non-Regulated markets Manufacturers of more tha
Slide 6: Driving Sustainable Growth: Strategic Imperatives
DRIVING SUSTAINABLE GROWTH: STRATEGIC IMPERATIVES o Focus on R&D to develop niche, o Development of intermediates for high-value/high-volume APIs and APIs intermediates o Reducing dependence on China to o Capacity expansion move towards self sufficiency o Compliance with Global Regulatory COST o Opt
Slide 7: Driving Sustainable Growth: Regulatory Compliance
DRIVING SUSTAINABLE GROWTH REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards of manufacturing and quality at its all plants FORMULATIONS ACCREDITATIONS API ACCREDITATIONS Approved by 15 countries including MHRA (U
Slide 8: Operational Performance
OPERATIONAL PERFORMANCE
Slide 9: Operational Highlights: APIs Segment-wise Revenue Mix
OPERATIONAL HIGHLIGHTS APIs SEGMENT-WISE REVENUE MIX Q3 FY 2023-24 (₹ LAKHS) 9M FY 2023-24 (₹ LAKHS) Anti- Infective Anti- Diabetic 44.20 85.68 161.56 133.59 16.76 926.51 Anti- Infective 568.45 Antibiotic-Urological 2,747.67 279.76 Antibiotic-Urological Anti-Hypertensive 740.50 Anti-Hypertensive Neu
Slide 10: Operational Highlights: APIs Market-wise Revenue Mix
OPERATIONAL HIGHLIGHTS APIs MARKET-WISE REVENUE MIX Q3 FY 2023-24 (₹ LAKHS) 9M FY 2023-24 (₹ LAKHS) 9,766.71 3,149.45 Export Sales Export Sales Local Sales Local Sales 4,967.51 14,081.05 Total ₹ 8,117 Lakhs Total ₹ 23,848 Lakhs Note: Excluding solvent and scrap sales and includes API consumed for pr
Slide 11: Formulations Region-wise Sales Break-up
OPERATIONAL HIGHLIGHTS Formulations REGION-WISE SALES BREAK-UP Q3 FY 2023-24 (₹ LAKHS) 9M FY 2023-24 (₹ LAKHS) Africa Africa 1,344.81 453.67 172.52 262.46 Canada Canada 677.18 1,637.37 1,916.98 Latem Latem 5,336.91 South Africa South Africa 53.21 Southeast Asia Southeast Asia 65.90 UK UK 26.45 Middl
Slide 12: Formulations Product-wise Revenue Mix
OPERATIONAL HIGHLIGHTS Formulations PRODUCT-WISE REVENUE MIX Q3 FY 2023-24 (₹ LAKHS) 9M FY 2023-24 (₹ LAKHS) 2,953.36 8,043.08 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 4,726.02 10,864.93 Total ₹ 7,679 Lakhs Total ₹ 18,908 Lakhs Note: Excluding Scrap Sales 12
Slide 13: Financial Performance
FINANCIAL PERFORMANCE
Slide 14: Financial Highlights: Consolidated Summary
FINANCIAL HIGHLIGHTS Consolidated Q3 FY Q2 FY Q3 FY PARTICULARS 2023-24 2023-24 2022-23 Summary Revenue from Operations 16,135 15,259 16,022 o Revenue from operations increased to ₹ 16,135 Lakhs in Q3 FY EBITDA 2,358 2,283 1,384 2023-24 as compared to ₹ 16,022 Lakhs in Q3 of FY 2022-23. Net Profit 1
Slide 15: Financial Highlights Snapshot
FINANCIAL HIGHLIGHTS SNAPSHOT 50,980 55,405 48,813 43,346 27,211 SALES/OTHER INCOME (₹ LAKHS) 2020-21 2021-22 2022-23 H1 2023- 9M 2023- 8,739 8,178 24 24 4,672 5,272 EBITDA * 2,914 (₹ LAKHS) 2020-21 2021-22 2022-23 H1 2023- 9M 2023- 624 608 601 24 24 512 377 FINANCE COSTS (₹ LAKHS) 2020-21 2021-22 2
Slide 16: Financial Highlights: Building Shareholder Value Year on Year
FINANCIAL HIGHLIGHTS BUILDING SHAREHOLDER VALUE YEAR ON YEAR RoE (%) RoCE (%) 28.3 22.4 25.3 7.9 9 12.1 20.1 EBITDA & EBITDA Margin 9.4 Net Debt/Equity 6.3 7.5 (₹ Lakhs, %) (X) 2020-21 2021-22 2022-23 H1 9M 16.62 18.30 2023-24 2023-24 14.95 Return on Networth/Equity 14.83 Return on Capital Employed
Slide 17: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS PARTICULARS 9M FY 2023-24 FY 2022-23 FY 2021-22 FY 2020-21 FY 2019-20 Revenue from Operations 42,851 55,098 47,752 49,181 35,949 Equity Share Capital 4,821 4,821 4,821 4,325 4,324 Other Equity 42,555 39,104 37,796 20,177 14,643 Net Worth 47,376 43,925 42,617 24,503
Slide 18: Governance: Board of Directors
GOVERNANCE BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. ADARSH RAJENDRA SOMANI MRS. MAMTA BIYANI MR. NARAYAN ATAL EXECUTIVE VICE CHAIRMAN DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR DR. SIDDHAN SUBRAMANIAN DR. SUNITA BANERJI MR. SUSHEEL SOMANI MR. VARUN SURENDRA SOMANI INDEPENDENT DIRECTOR INDE
Slide 19: Contact Us
CONTACT US ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Developmen